NASDAQ •
Healthcare •
Biotechnology •
Quote as of 05/18/2026 16:00
Company Profile
IndustryBiotechnology
SectorHealthcare
ExchangeNASDAQ
Market Capitalization9,594.23 mln
Float64.14 mln
Earnings Date06/08/2026
Piotroski F-Score
3
/ 9
Below average
Relative Strength
29
/ 100
Underperforming
Debt / Equity
0.00
Debt-free
ROE
-175
Deeply negative
Dividend Yield
0.00%
No dividend
DPS
0.00
No dividend
Business Description
ABIVAX is a Paris-based drug development company founded in 2013, focused on creating treatments that work with the body's own immune system to manage long-term inflammatory conditions. Its most advanced medicine, obefazimod, is currently being tested in late-stage trials for ulcerative colitis and earlier-stage trials for Crohn's disease.
